Azar's HHS: Generic Certainty, REMS Fixes Can Lower Drug Prices
Executive Summary
During Senate Health, Education, Labor and Pensions Committee hearing on the former Eli Lilly executive's nomination for HHS Secretary, Alex Azar said department should consider whether REMS still necessary upon generic entry.
You may also be interested in...
Are 180-Day Exclusivity Changes Moving Out Of Drug Pricing Plans?
US FDA softens its tone on idea and encourages industry to voice its (predominantly negative) opinion publicly.
Are 180-Day Exclusivity Changes Moving Out Of Drug Pricing Plans?
US FDA softens its tone on idea and encourages industry to voice its (predominantly negative) opinion publicly.
Opioid, NME, And Generic Drugs Changes Plotted In US FDA's 2018 Policy Roadmap
‘Better informed patients,’ ‘drug competition,’ ‘biosimilar innovation’ – as well as nutrition and tobacco goals will be achieved through guidances, promotional plans and other items FDA will develop over the next year.